Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19502303 | 0.85 | CYP17A1 (0.77) | CYP17A1 | |
| SCHEMBL3784539 | 0.84 | CYP17A1 (0.72) | CYP17A1 | |
| SCHEMBL13735913 | 0.84 | CYP17A1 (1.00) | CYP17A1 | |
| SCHEMBL13736429 | 0.84 | CYP17A1 (1.00) | CYP17A1 | |
| SCHEMBL13735832 | 0.83 | CYP17A1 (1.00) | CYP17A1 | |
| SCHEMBL13834154 | 0.82 | CYP17A1 (1.00) | CYP17A1 | |
| SCHEMBL13735476 | 0.82 | CYP17A1 (1.00) | CYP17A1 | |
| SCHEMBL13834163 | 0.82 | CYP17A1 (1.00) | CYP17A1 | |
| SCHEMBL16689922 | 0.82 | CYP17A1 (1.00) | CYP17A1 | |
| SCHEMBL19502304 | 0.81 | CYP17A1 (0.71) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | claimed |
| US-9029399-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-05-12 | — | — | US | claimed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | claimed |
| CN-103649073-A | 17alpha-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2014-03-19 | — | — | CN | claimed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | claimed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | claimed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| CN-103649073-A | 17alpha-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2014-03-19 | — | — | CN | disclosed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | CYP17A1 1/4885 |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | CYP17A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.